Wedbush analyst Liana Moussatos lowered her price target for Aquestive Therapeutics to $34 from $37 following the company's presentation at the American Epilepsy Society 2019 Annual Meeting and Investor & Analyst Libervant Update Forum. Moussatos tells investors that based on the Libervant clinical dataset, she anticipates approval and project annual sales of $204M in 2024. She says she came away from the event confident about the company's positioning ahead of potential Libervant U.S. launch in 2020. The analyst maintains an Outperform rating on the shares.